This suggests that TCL1A is processed and presented on the surface of CLL cells for recognition by cytotoxic T cells and that it can serve as a novel target for vaccinations or in other immune-therapeutic strategies such as TCL1A-targeting CAR T cells [118]. The gene discussed is TCL1A; the disease is B-cell chronic lymphocytic leukemia.